Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
4.883
+0.133 (2.80%)
Nov 5, 2024, 1:16 PM EST - Market open
Elicio Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 12.17 | 11.9 | 5.63 | 7.54 | 3 | 2.8 |
Research & Development | 29.16 | 23.85 | 18.1 | 17.93 | 12.72 | 9.54 |
Operating Expenses | 41.33 | 35.75 | 23.73 | 25.47 | 15.72 | 12.34 |
Operating Income | -41.33 | -35.75 | -23.73 | -25.47 | -15.72 | -12.34 |
Interest Expense | -0.09 | -1.06 | -3.6 | -0.88 | - | - |
Interest & Investment Income | 0.61 | 0.37 | 0.07 | 0 | 0.01 | 0.08 |
Currency Exchange Gain (Loss) | 0.36 | 0.2 | - | - | - | - |
Other Non Operating Income (Expenses) | 1.78 | 0.43 | -0.95 | -0.05 | - | - |
EBT Excluding Unusual Items | -38.67 | -35.8 | -28.21 | -26.4 | -15.71 | -12.26 |
Other Unusual Items | 0 | 0.61 | 0 | - | - | - |
Pretax Income | -38.67 | -35.2 | -28.21 | -26.4 | -15.71 | -12.26 |
Net Income | -38.67 | -35.2 | -28.21 | -26.4 | -15.71 | -12.26 |
Net Income to Common | -38.67 | -35.2 | -28.21 | -26.4 | -15.71 | -12.26 |
Shares Outstanding (Basic) | 10 | 5 | 0 | 15 | 11 | 4 |
Shares Outstanding (Diluted) | 10 | 5 | 0 | 15 | 11 | 4 |
Shares Change (YoY) | 896.37% | 1500.08% | -97.93% | 42.39% | 172.21% | - |
EPS (Basic) | -4.01 | -6.96 | -89.27 | -1.73 | -1.46 | -3.11 |
EPS (Diluted) | -4.01 | -6.96 | -89.27 | -1.73 | -1.46 | -3.11 |
Free Cash Flow | -36.22 | -32.76 | -22.83 | -24.46 | -16.9 | -9.78 |
Free Cash Flow Per Share | -3.76 | -6.48 | -72.26 | -1.60 | -1.58 | -2.48 |
EBITDA | -41 | -35.36 | -23.34 | -25.22 | -15.53 | -12.23 |
D&A For EBITDA | 0.33 | 0.38 | 0.39 | 0.25 | 0.19 | 0.11 |
EBIT | -41.33 | -35.75 | -23.73 | -25.47 | -15.72 | -12.34 |
Source: S&P Capital IQ. Standard template.
Financial Sources.